INmune Bio's MINDFuL Trial Featured at AD/PD 2026 as Successful Example of Precision Approach to Clinical Trials Targeting Inflammation in Early Alzheimer's Disease.

INmune Bio's MINDFuL trial was featured at AD/PD 2026 as a successful example of targeting inflammation in early Alzheimer's disease. The trial's biomarker enrichment strategy aligned with the mechanism of action, identifying patients most likely to respond. Dr. Malú Gámez Tansey, a neurology professor, highlighted the trial as a blueprint for Alzheimer's drug development. INmune Bio is advancing a Phase 2b/3 registrational program for XPro1595 in enriched early Alzheimer's patients.